Advertisement

Topics

Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology

17:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Interim CATALYST Study Findings Presented at PFF Summit – Veracyte, Inc. (NASDAQ: VCYT) announced that new data for the Envisia™ Genomic Classifier were presented today and demonstrate that the test – in rea...

Other Sources for this Article

Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Jackie Cossmon, 650-243-6371
jackie@veracyte.com

NEXT ARTICLE

More From BioPortfolio on "Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...